ORIGINAL RESEARCH ARTICLE

Divergent Neuroimmune Signatures in the Cerebrospinal Fluid Predict Differential Gender-Specific Survival Among Patients With HIV-Associated Cryptococcal Meningitis

- 1 Samuel Okurut^{1,2*}, David R Boulware³, Elizabeth Okafor³, Joshua Rhein³, Henry Kajumbula ²,
- 2 Bernard Bagaya ⁵, Freddie Bwanga ², Joseph O Olobo⁵, Yukari C Manabe^{1,4}, David B Meya^{1,3,6},
- 3 and Edward N Janoff^{7,8} for ASTRO trial team.
- 4 ¹Translation Sciences Laboratory, Research Department, Infectious Diseases Institute, Makerere
- 5 University, Box 22418, Kampala, Uganda
- 6 ²Department of Medical Microbiology, School of Biomedical Sciences, College of Health Sciences,
- 7 Makerere University, 7072, Kampala, Uganda
- 8 ³Division of Infectious Diseases and International Medicine, Department of Medicine, University of
- 9 Minnesota, Minneapolis, MN, 55455, USA
- 10 ⁴Division of Infectious Diseases, Department of Medicine, John Hopkins University School of
- 11 Medicine, Baltimore, Maryland, MD, 21205, USA
- 12 ⁵Department of Immunology and Molecular Biology, School of Biomedical Sciences, College of
- 13 Health Sciences, Makerere University, Box 7072, Kampala, Uganda
- ⁶Department of Medicine, School of Medicine, College of Health Sciences, Makerere University, 7072,
- 15 Kampala, Uganda

19

22

26

28

30

- ⁷Mucosal and Vaccine Research Program Colorado, Department of Medicine, Division of Infectious
- 17 Diseases, University of Colorado Denver, Aurora, Colorado, 80045, USA
- 18 Benver Veterans Affairs Medical Center, Denver CO, 80045, USA
- *Correspondence to: Samuel Okurut, Infectious Diseases Institute, Makerere University, Box 22418,
- 21 Kampala, Uganda. Email: <u>okuruts@gmail.com</u>, Mobile: +256-782-003931.
- 23 Key words (maximum 8): cryptococcal meningitis 1, gender survival 2, Cerebrospinal fluid 3,
- neuroimmune signatures ₄, Principal Component Analysis ₅, IL-5 ₆, CXCL10/IP-10 ₇, CCL11/Eotaxin ₈
- 27 Number of words: (4864 words, maximum 12,000 words)
- 29 Number of Figures and Tables: (9 Figures and or Tables, maximum 15 figures or tables)

ABSTRACT (310 of 350 words)

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

Survival among people with HIV-associated cryptococcal meningitis (CM) remains low, exceptionally among women with the increased threat of death on current optimal use of antifungal drugs. Cryptococcus dissemination into the central nervous system (CNS) prompts a neuroimmune reaction to activate pathogen concomitant factors. However, no consistent diagnostic or prognostic immune-mediated signature is reported to underpin the risk of death or mechanism to improve treatment or survival. We theorized that the distinct neuroimmune cytokine or chemokine signatures in the cerebrospinal fluid (CSF), distinguish survivors from people who died on antifungal treatment, who may benefit from tailored therapy. We considered the baseline clinical disease features, cryptococcal microbiologic factors, and CSF neuroimmune modulated signatures among 419 consenting adults by gender (biological sex assigned at birth) (168 females and 251 males) by 18 weeks of survival on antifungal management. Survival at 18 weeks was inferior among females than males (47% vs. 59%; hazard ratio HR=1.4, 95% CI: 1.0 to 1.9, and p=0.023). Unsupervised principal component analysis (PCA) demonstrated the divergent neuroimmune signatures by gender, survival, and intragender-specific survival. Overall, females displayed lower levels of PD-L1, IL-1RA, and IL-15 than males (all p≤0.028). Female survivors compared with those who died, expressed significant fold elevations in levels of CSF (CCL11 - myeloid and CXCL10 - lymphoid chemokine (in both p=0.001), and CSF Th1, Th2, and Th17 cytokines. In contrast, male survivors expressed distinctly lower levels of CSF IL-15 and IL-8 compared with those who died. Survivors of either gender demonstrated a significant increase in the levels of immune regulatory element, IL-10. In the finale, we classified divergent neuroimmune key signatures in CSF by gender, survival, and intragenderspecific survival among people with HIV-associated cryptococcal meningitis. These intragenderspecific survival associated-neuroimmune signatures, suggests the discrete role of gender immune regulating mechanisms as the possible targets for interventions to advance therapy to improve survival among people with HIV-associated cryptococcal meningitis.

1 INTRODUCTION

58

59

60

61 62

63 64

65

66

67 68

69 70

71

72 73

74

75 76

77

78

79

80

81

82

83

84 85

86 87

88 89

90

91

92 93

94 95

96

97

98 99

100

101

102

103

104

105

Co-infection with the fungus Cryptococcus neoformans remains an important contributor to death among people with advanced HIV/AIDS worldwide, reported with the existing ideal use of antifungal medications ^{1,2}. The reported global HIV-associated cryptococcal meningitis (CM) survival rates vary by location based on existing HIV prevalence rates. In Europe and North America, with the low prevalence of people with HIV, both the incidence and mortality rates of CM are lowest ³, in contrast, to low and middle-income countries, especially in Africa with the highest prevalence of people with HIV ³⁻⁵. In countries with high frequency of people with HIV in Africa, like Uganda, Botswana, and South Africa, the 10-week survival rates can fall below 50% ^{3,5-8} reported among closely monitored research settings, with deaths occurring within days to weeks, and sometimes, up to months after diagnosis ^{2,9,10}. The high mortality among closely monitored patients with CM may be worrisome, for patients undertaking treatment in public health settings where specialized diagnosis and close treatment monitoring may be a challenge. These observations rank highly the importance of early immune response as possible intervention to control fungal infection in supporting better survival ¹⁰.

The Casadevall and Pirofski damage response framework paradigm points to the role of the pathological processes in influencing host response mechanisms to shape the infection and disease outcome in sequelae 11,12. That the replicating pathogen eliciting unregulated immune activated mechanism (role of immune regulation), mediate pathways that lead to host self-directed damage responses that lead to poor outcome. And that replicating pathogen in a state with immune inhibition or in the absence of the pathogen-specific induced response (case of severe immune suppression), that pathogen-associated virulence factors lead to host damage responses that lead to poor outcomes. Suggesting that improved outcome is achievable in a combined therapy involving an effective pathogen-specific target therapy (e.g., antifungals) combined with immune-based treatment to modulate immune homeostasis.

In the immunopathogenesis observations, cryptococcal dissemination into the central nervous system (CNS) tissues and CSF across the blood-brain barrier ^{13–15} leads to activation of CNS resident neuroimmune cells (astrocytes, microglial cells, local macrophages, dendritic cells, and lymphocytes). In the process, locally activated immune cells produce activating chemoattractant proteins (e.g., CCL11/Eotaxin, CXCL10/Interferon inducible protein 10 (IP-10) 16,17 and other inflammatory mediators (e.g., IL-15, IL-8/CXCL8) ¹⁸. During cryptococcal infection, CNS infiltrating immunocytes, especially T and B cells ^{19,20}, may extravasate blood vessels and lymphatic channels to induce neuroimmune activation, inflammation, and meningoencephalitis. Intracerebral and intrathecal activated cytokine and chemokine production influence neuroimmune milieu-mediated responses, that shape fungal clearance, ensuing immunopathological processes, clinical phenotype, and death outcome

Among studies reporting cases by gender, the majority of cryptococcal meningitis is diagnosed among males ^{2,7,9,19,26–44}. Of note, few studies to date since widespread ART rollout specifically address selective survival by gender (only five including the current study) 7. Only recent data, from 2021 reveal that the proportion of females who succumb to fungal disease was higher than in males even in the presence of optimized antifungal and antiretroviral therapy 9. Since widespread ART rollout, no such differences in gender-specific survival were reported ^{26,44}. To date, no clear immunopathogenic mechanisms have been proposed to explain the divergence in survival by gender despite access to current optimal antifungal treatment and ART.

In CM, males show increased expression of innate chemokines and cytokines in the CSF associated with increased trafficking of innate lymphoid and myeloid cells compared with females, 7. However, these differences were not evaluated in relation to gender-specific survival. Furthermore, the differences in the host responses to the vaccine induced antigens have been reported by gender in both humans and animals 45,46, showing elevation in cytokine production, endocrine, and metabolic

parameters in females compared with males. Nevertheless, in cryptococcal meningitis, the cryptococcal fungal burden, white cell counts, and protein in CSF, and the white cells, and CD4⁺ T cell numbers in blood were similar by gender⁷. The cryptococcal host immune evasion mediating factors, e.g., Cryptococcus fungal vomocytosis and the cryptococcal intracellular fungal proliferation in the cryptococcal infected macrophages, were similar by gender ⁴⁷.

We evaluated CSF-specific soluble cytokine, chemokine, and immunoregulatory responses to cryptococcal meningitis between females and males overall, and the differences in these neuroimmune responses in relation to survival by gender (Biological sex assigned at birth). We hypothesized that CSF neuroimmune cytokine and chemokine signatures would differ between females and males and across survival. In the CSF at baseline, we characterized representative Th1, Th2, Th17, Tfh cytokine, and innate myeloid-neutrophils activation regulating cytokines, and immune checkpoint markers (PD-L1) among people who survived or died during the 18 weeks of follow-up. We identified discrete differences in patterns of neuroimmune mediators by gender and by intragender-specific survival at the site of infection in the CSF.

MATERIALS AND METHODS 2

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127 128

129

130

131

132

133 134

135

136

137

138 139

140

141

142

143 144

145 146

147

148

2.1 Participants, Sites, and Setting

We enrolled 419 participants from a cohort of adults with CM enrolled to receive meningitis treatment in the Adjunctive Sertraline for the Treatment of HIV-Associated Cryptococcal Meningitis trial (ClinicalTrials.gov: NCT01802385). The trial was conducted between 2015 - 2017 at the Infectious Diseases Institute (Administrative site) and at Mulago and Kiruddu National Referral Hospitals (patient catchment sites) in Kampala, Uganda ^{2,48}. The participants were selected based on gender and available survival-specific data for cross-sectional analyses with reference to 18 weeks of survival after cryptococcal meningitis diagnosis. The majority (94%; 168 females and 251 males) had complete demographic, clinical, and CSF datasets. Participants or their surrogates gave informed written and signed consent under protocols approved by the institutional review board of Makerere University and the University of Minnesota Medical School. Enrolled in the study were people ≥18 years of age, with a confirmed diagnosis of HIV-associated cryptococcal meningitis co-infection as previously described ^{49,50}. Only participants whose survival status was known at censoring or at study termination at 18 weeks of follow-up (379 of 419; 90.5%) were included in the survival sensitivity analyses. Of note, parent cohort survival did not differ statistically between either sertraline randomized participants or those on standard therapy alone ².

2.2 **Specimen Preparation**

CSF was drawn from lumbar punctures at diagnosis of CM prior to antifungal therapy initiation. The CSF specimens were spun to pellet out cells. The CSF supernatant was stored in a -80 °C freezer prior to thawing for testing using Luminex. At enrolment, all participants in the current study were antifungal treatment naïve.

Luminex Cytokine and Chemokine Immunophenotyping 2.3

A representative sample of cytokines, chemokines, and checkpoint regulators was measured in CSF diluted in a 1:2 ratio based on the R&D Human XL Cytokines Discovery Premixed Kit platform as per the manufacturer's recommendations (R&D, Minneapolis, MN). The T helper 1 (Th1) cytokines were tumor necrosis factor-alpha (TNF-α), interferon-gamma (IFN-γ), interleukin 2 (IL-2), IL-12p70, with soluble CD40-Ligand/TNFSF5. The Th2 cytokines were IL-4 and IL-13. T follicular helper cytokines were IL-6 and IL-10. The Th17 cytokines included was IL-17A. Cytokines derived from

- 149 innate lymphoid and myeloid cells were IL-15, IL-8, IL-1 RA/IL-1 F3. The inflammatory mediating
- chemokines primarily derived from microglial and astrocytes mediating neuroinflammation in 150
- cryptococcal meningitis were CXCL10 lymphoid cells mediating chemoattraction ^{51,52} and CCL11 151
- mediating myeloid cells (Eosinophils) chemoattraction ^{53,54}. The IL-8 mediating neutrophils activation 152
- and chemoattraction 55. The immune checkpoint molecules were programmed death ligand 1 (PD-153
- L1/B7-H1) ⁵⁶ and immune regulatory cytokine IL-10 ⁵⁷. 154

2.4 **Statistical Analysis**

155

156 157

158

159 160

161

162

163 164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182 183

184

185

186 187

188

189

190

191

192

Data were analyzed using GraphPad Prism version 9.3.0, GraphPad Software, LLC for Macintosh (San Diego, California, USA). The databases were compiled using Microsoft Excel. The data variability was visualized using unsupervised Principal Component Analysis, (PCA) using Eigenvector covariates projection on biplots as described elsewhere ^{58–61}. Further interrogation of the individual or independent principal component clustering and variability, factor differences, and interactions or associations of independent predictor variables by gender and by survival were performed using univariate and multivariate analyses.

Univariate analytic methods comprised pairwise comparisons using Mann-Whitney nonparametric U test that compared arithmetic medians and unpaired parametric t-test that compared arithmetic means. In this context of non-normally distributed population variables, statistical differences were reported based on the difference in the sample medians with interquartile ranges (IQR). The univariant difference in the survival outcome or survival risk was determined using Kaplan-Meier/Log-rank test (Mantel-Cox Chi-Square test) or Mann-Whitney U-test. The difference in binary outcome was determined using Fisher's exact Chi-square test or Mann-Whitney U-test.

In multivariate models, data were Log₂ transformed to normalize the variable prior to the statistical interrogation using multivariate factor analysis and or survival-adjusted logistic regression least square models that measure the risk of likelihood (proportional hazard ratios). In all models, missingness was not imputed. In this context, statistical significance in both the univariate and the multivariate models were based on difference among variables in the original available dataset among participants. The statistical level of the significantly different covariates was reported at a p-value < 0.05 and at a 95% level of confidence. The rigor of our interrogations included a large sample size (N=419), controlled comparative covariables at nearly a 1:1 ratio, and minimal missingness with approximately 94% data completeness in gender analyses and approximately 90% data completeness in the 18 weeks of survival analyses.

3 **RESULTS**

3.1 Baseline Demographics, by Gender

Consistent with published reports (Figure 1), among 419 participants studied with HIVassociated CM, the majority were males, who were older and heavier than females (Table 1). About half of these participants were on ART for a median of 1.6 months (IOR; 0 -22 months). Neurologic abnormalities predominated among clinical signs and symptoms, with almost all describing headache for one to four weeks, a third reporting changes in mental status, and a half with abnormal Glasgow Coma Score (GCS<15), with each variable reported at comparable frequencies in males and females.

As anticipated, CD4⁺ T cell numbers in circulation were low, but were marginally higher in females than males, as were platelet counts and hemoglobin levels (Table 1). CSF protein was not consistently elevated, and WBC counts were low, despite a high burden of yeast. Each result was generally comparable by gender, except CSF glucose which tended to be lower among females than males (Table 1).

3.2 The 18 Weeks Survival on Antifungal Treatment

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

In the parent trial for this analysis, males and females from Uganda and South Africa were randomized 1:1 to receive sertraline (an antidepressant with putative antifungal activity) or standard treatment but showed no differences in survival between treatment groups at 18 weeks ². An initial analysis by gender of an expanded data set, from which this current report is derived, showed significantly lower survival among 400 females vs. 577 males (at 50% vs. 57% survival, respectively) at 10 weeks, unadjusted (Hazard Ratio (HR) = 1.20; 95% CI, 1.00-1.45; p=0.050) ⁷. These differences were greater vet in this current subset extended to 18 weeks of observation. Survival among females was 47% (71/150 females) vs. 59% among males (136/230 males) (Mantel-Cox proportional hazard ratio (HR)=1.4 (95% confidence interval, CI: 1.0–1.9); p=0.023) (Figure 2). Of note, survival was similar among males and females in two earlier studies reported prior to ART optimization (before 2015) but lower among females in two studies reported after ART optimization (after 2015), which include the current report (Figure 1-2). In the current study, survival overall, and by gender did not differ by ART experience (data not shown).

Survival was similar by gender in the first two weeks of antifungal therapy (Figure 2). However, survival diverged thereafter, remaining consistently lower among females throughout the 18 weeks of observation. As noted, baseline demographics, signs and symptoms, blood and CSF analytes, and cryptococcal fungal burden were relatively similar among participants by gender and by survival (Table 1). Thus, we considered whether the concentrations and the composition of neuroimmuneinduced factors at the site of severe cryptococcal disease in the CSF could underlie subsequent differences in survival by gender over time of observation.

3.3 Significant Differences in Neuroimmune Signatures in Cerebrospinal Fluid by Survival, Gender, and Intragender-Specific Survival.

At baseline, we performed unsupervised Principal Component Analysis (PCA) as a primary approach to visualize the data variability and to explore potential unbiased differences in data clustering by gender, survival, and gender-specific survival (Figure 3). The PCA identified individual clusters that offered opportunities to structure downstream data analyses of the indicated model outcomes. The members in the cluster aggregated based on common attributes of the datasets showing high variability and distinct distribution of cytokines and chemokines between females and males (Figure 3A), between survivors and participants who died (Figure 3B), and within gender survival, among females (Figure 3C) and among males (Figure 3D). Eigenvector projections on principal components 1 and 2 (PC1 and PC2 respectively) indicated a high probability of neuroimmune variables predicting association with gender and survival outcome (Figure 3 A-D). High Eigenvalues >5 indicate the high capability of the selected covariables in predicting model-associated outcomes (Table below Figure 3). For each of the comparative groups, almost all showed such high Eigenvalues and, thereby, the separation between determinants in each group. These distinct patterns for PC1 and PC2 were closely correlated among participants by gender, subject by survival, and females by survival but less so for male survival in which 3 clusters were identified (correlation data not shown). Due to the striking data clustering observed in these groups, we next determined the specific neuroimmune factors contributing to the observed patterns using supervised univariate and multivariate data interrogation approaches.

3.4 Innate Neuroinflammatory Cytokines in the Cerebrospinal Fluid Differ by Gender

The CSF of females with CM at baseline had significantly lower levels of selected innate cytokines than that of their male counterparts, particularly IL-1RA and IL-15, TNF-α and immune checkpoint, PD-L1 (all p<0.050) (Table 2). The remainder of the cytokines and chemokines interrogated did not differ significantly by gender but tended to be lower still among females than

238 males (Table 2). We next considered whether such gender-specific differences were associated with 239 the differences in survival by gender.

Divergent Baseline Neuroimmune Cytokine Signature Predict Intragender Survival

3.5.1 (i). Female Gender-Specific Survival Attributes

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263 264

265

266

267 268

269

270

271

272

273

274

275

276

277

278

279

280

281

A number of relevant factors differed between females who survived or died during the 18 weeks of observation. The circulating CD4⁺ T cell numbers were generally very low, but median CD4⁺ T cells were 31 cells/μL vs. 14 cells/μL among females who survived vs. those who died (p=0.009) but did not differ by survival in males (data not shown). Using several alternative models, and after adjusting for cytokines (Table 4 model 1), CXCL10 and CCL11 consistently predicted female survival but not in males. These soluble immune factors were consistently higher in magnitude among female survivors compared to those who died (Table 3). The levels of CXCL10 were significantly higher among females who survived than those who died, (p=0.013) (Table 3). By survival, CXCL10 levels in females who survived correlated with the number of CSF white cell counts (r=0.292, 95% CI: 0.067-0.488; p=0.010), but not in males (Supplementary Figure 1). The fungal burden (CFUs) did not correlate with CXCL10 levels by either gender or gender-specific survival (data not shown).

The level of CCL11 (a chemoattractant produced by activated astrocytes, lymphocytes, and macrophages), was significantly higher in female survivors than in those who died, but not among males (Table 3). After adjusting for other cytokines, higher CCL11 expression still predicted female but not male survival (**Table 4, Model 1**). T cell-related factors (e.g., IL-12p70, IL-17A, and IFN-γ) in the univariate models were also consistently increased in females who survived compared to those who died, but not in males (Table 3). The levels of other cytokines and the neutrophils chemokine IL-8 showed no difference among females by survival (Table 3). Only the IL-10 level was increased in both genders among those who survived in univariable analysis (Table 3). However, after adjusting for other factors, the levels of IL-10 expression were correlated with only female survival, but not with male survival (Table 4, Models 2 and 3), as was IL-2 (Table 4, Model 3).

In summary, although immune parameters were lower among all females vs. males, the females who survived showed consistently elevated levels of both myeloid-derived chemokines (CCL11), lymphoid-derived chemokine (CXCL10), T cell-derived cytokines, and the regulatory molecule PD-L1, the differences that were mostly distinct to survival in females, but not in males (Supplementary Figure 1).

3.5.2 (ii). Male Gender-Specific Survival Attributes

Males who survived had significantly higher hemoglobin compared with those who died, even after adjusting for the platelet counts and CD4+ T cell counts (Table 4, Model 3). Males, but not females, who survived had significantly lower IL-15 than those who died (Table 3), even after adjusting for other cytokines (Table 4, all Models). The IL-15 levels were independent of fungal burden (CFUs) and CSF white cell counts (data not shown). After adjusting for other factors, lower levels of the neutrophil chemoattractant IL-8 also consistently predicted male survival but not among females (Table 4, Models 1, 3-4). Unlike in males, neither low levels of IL-15 nor IL-8 were associated with survival in females. As noted above, elevated levels of regulatory IL-10 were associated with survival in both genders but did not correlate with male survival (Supplementary Figure 1).

4 **DISCUSSION**

In a large cohort of adults with CM in Uganda on anti-fungal therapy, survival among females was significantly lower compared with that of their male counterparts. Evaluating gender-specific mortality is uncommon in this context (only 5 including the current 21 studies; Supplemental Table

S1), Unlike two previous studies which showed no difference in mortality by gender reported ^{26,44}, the two studies showing such a differences ^{7,42} were performed in people treated with antifungal therapy, which helps control fungal burden. Combining antifungal drugs with immunomodulatory interventions could limit the fungal assault on the CNS, illustrated by brain lesions from magnetic resonance imaging and from autopsy examinations among cases with neurological focal infections 62-65. With appreciable control of fungal burden, immune responses may be the more prominent determinant of clinical outcomes.

282

283 284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306 307

308

309

310

311

312 313

314

315 316

317

318

319

320

321

322

323

324

325

326 327

328 329

330

We have identified distinct immune-biological differences in CSF by gender and genderspecific survival. The signatures associated with survival in females are distinctive from those in males. These differences were independent of baseline clinical features and cryptococcal fungal burden (CFUs). Most consistent in both the univariate and in multivariate gender-associated survival predictive models were the lower levels of CSF CXCL10/IP-10 and CCL11/Eotaxin that distinguished females who died from survivors, but not males. In contrast, high levels of IL-15 and IL-8 differentiated males who died matched to those who survived, but not females. Several T cell cytokines (IFN-y, TNFα, IL-13, and IL-17A) similarly exhibited diminished levels of expression in females who died matched survivors, but not in males. Lower levels of immune regulatory IL-10 expression were linked with an increased threat of death in both genders. Thus, the biological significance of gender-specific CSF immune signatures suggested among participants with CM may underlie important immune-based mechanisms indispensable to improving antifungal treatment and survival predominantly in women with demonstrated distinct survival-associated cytokine and chemokine patterns.

Consistent with the univariate model observations, improved survival at 2-10 weeks was associated with elevation in the levels of soluble CSF cytokines Th1 IL-2, IFN-γ, TNF-α, Th2 IL-4, and Th17 IL-17A, together with innate IL-6 cytokine 66,67. Soluble T-lymphokines levels in CSF are proposed to derive from CXCL10 ⁶⁸ and CCL11 ⁶⁹ mediated stimulation of CNS resident immune cells. Moreover, the use of cryptococcal antigens (such as GXM) to stimulate peripheral immunocytes demonstrated, that patients with improved 10 weeks survival had increased expression of these cytokines among polyfunctional differentiated CD4 T cells ⁶⁷. Other chemokines demonstrated to predict improved survival included the elevated levels of monocytes chemotactic protein-1 and macrophages inflammatory protein-1 ⁶⁶. Despite demonstrated correlates of survival in the peripheral circulation ^{70,71}, the importance of characterizing immune responses in the CNS, at the foci of infection, cannot be underestimated since CNS responses in larger studies do not often correlate with those in the peripheral circulation ^{70,71}. The disparity between peripheral and CNS observed responses is a characteristic indicator of local mechanisms that influences responses. Compartment-specific responses have been noted previously ^{19,20} and argue that we should be investigating the response in CSF. Thus, the current study is unique in characterizing the distinctive neuroimmune signatures defining survival by gender in CNS, at the foci of disease.

In theory, the microbial invasion of the CNS activates resident immune cells to produce neuroimmune cellular activating cytokines, chemoattractant chemokines, and surrounding tissue basal cellular immune mediators (prostaglandins, leukotrienes, et cetera). Diverse effector cells include resident microglial, astrocytes, oligodendrocytes, CNS surveillance phagocytes (monocytes, macrophages, neutrophils), dendritic cells, adaptive T and B cells, innate (natural killer cells), and basal barrier epithelial cells ⁷². Other cells may be drawn by extravasation and diapedesis through the protective vascular barriers to infiltrate the CNS in response to infection and/or to ensuing meningoencephalitis ^{19,20}. The consistent use of antifungal therapy in this study helps to control fungal replication and the burden of fungi ^{2,9,26,73}. With relatively effective antifungal therapy modeling immune factors highlights the role of the immune system in determining immune-mediated damage vs. protection in the CSF, and ultimately disease outcome ^{67,74,75}.

Although cryptococcal fungal burden and other clinical parameters in blood or in CSF did not differ by gender or gender-associated survival, increased production of IL-1RA, IL-15, and PD-L1 in

332 333

334

335

336 337

338

339

340

341

342

343

344

345

346

347

348 349

350

351

352

353

354

355

356

357

358 359

360

361 362

363

364

365

366 367

368 369

370

371

372

373

374

375

376

377

378 379

the CSF of males overall may have influenced their poor survival than in their female counterparts. Lower male but not female survival was associated with high levels of myeloid cytokines, including the pleiotropic IL-15 and neutrophil-activating factors IL-8, which may influence poor survival in males by the distinctive mechanisms. In literature, IL-8 expression derived from microglia in CNS in response to neuroinflammation ^{76,77}, from monocytes and autocrine IL-8 production by neutrophils enhances immune activation and cellular proliferation ¹⁸. The elevated intrathecal IL-15 and IL-8 in the CSF can enhance neutrophils-induced NETosis (Neutrophils traps). The increased neutrophil trap formation may propagate thrombotic vasculitis, cryptococcomas, and fungal occlusions in subarachnoid ventricular and arterial spaces in those with poor survival. Together IL-15 and IL-8 elevation can increase local inflammation in the brain, leading to vasculitis in subarachnoid spaces, interfering with blood supply, promoting ischemia, necrosis, and infarction of the brain tissue, and potentially leading to increased risk of death. Thus, the relatively high levels of IL-15 expression among males who died and the inverse relationship of IL-15 levels with those of immune regulatory IL-10 and immune checkpoint PD-L1 among males who died highlights the dynamic functional interrelationship of the potential loss of IL-15 immune regulatory function in influencing the greater risk of death among patients presenting with this neuroimmunological phenotype. Low levels of IL-15 may limit the mitotic division of especially fungal-infected macrophages which may attenuate the propagation of endogenous pathogens in quiescent cells ¹⁸. Thus, the observed low levels of IL-15 and IL-8 among male survivors may limit intracellular cryptococcal fungal replication potentially leading to low fungal burden and improved survival.

Among neutrophils activated factors that shape neuroimmune response and outcome in CNS infection and in sequelae include observations that neutrophil induced responses exacerbate tissue injury through self-directed host and pathogen-mediated mechanisms ^{78,79}. That neutrophil activation is associated with the propagation of tissue necrosis, hypoxia, and nutritional supply impairment especially among people with sepsis and in those with multiple organ failure, that underlie brain injury ^{78,79}. In this context, activation of neutrophil recruiting cytokines and chemokine, at the foci of infection, in the CNS is detrimental to the host ^{76,78}, leading to the release of toxic granules, that are destructive to connective tissues, leading to vasculitis with tissue necrosis, infarction, hypoxia, and potentially death. Indeed, in cryptococcal meningitis, neutrophilia in circulation was associated with poor survival outcome 80, brain hypoxia 15,81,82, subarachnoid blood vessel occlusion 83, brain tissue necrosis, and cerebellar infarction ⁶⁴. Subsequently, survivors of cryptococcal meningitis suffered longterm CNS abnormalities associated with impaired faculty observed in sequelae among people without HIV infection ^{62,84}. The persistent CNS abnormalities in sequelae noted in humans with fungal infections were similar to those observed among mouse models of Alzheimer's disease 85. In other fatal meningitis focal infections including tuberculosis meningitis and bacterial meningitis, neutrophils account for the majority of cells in the CSF 86,87. However, neither we nor others have characterized in detail the neutrophil myeloid lineages and role among CSF white cells in the setting of CM-associated survival.

Among key differences in female intragender survival with cryptococcal meningitis, survivors tended to shade into CSF relatively high amount of neuroimmune mediating soluble cytokine and chemokine responses across the panel. The higher levels of Th1 IL-2, IFN-γ, TNF-α, IL-12p70, Th17 IL-17A, and immune regulatory IL-10 may influence survival in females by distinct CXCL10 and CCL11 chemokine-stimulated mechanisms. In contrast to females who died, females with higher levels of the myeloid chemokine CCL11 and the lymphoid chemoattractant CXCL10 were more likely to survive, but not men. CXCL10 produced by astrocytes and microglia cells or by CNS resident monocytes, macrophages, and dendritic cells stimulates Th1 cytotoxic CD8 T cells, immune modulatory CD4 T cells, regulatory T cells, NK and regulatory B cells, and regulatory T cells via its CXCR3 receptor-mediated stimulation ⁸⁸. The cytotoxic response to infected macrophages is potentially enhanced in the presence of elevated chemokine in the central nervous, because infected

cells respond to chemoattractant proteins at the site of infection ^{89,90}, whereas immune regulatory cells can modulate inflammation and cellular activation to stimulate tissue recovery 91. Thus, independent of the baseline CSF cryptococcal CFUs and the baseline clinical features, the CCL11 and CXCL10 balance is critical in immune regulation of the Th1/Th2/17 balance, modulation of CNS cellular influx that is important in better survival of host with HIV-associated cryptococcal meningitis.

Interleukin (IL)-12 is observed as an important factor in the immune control of Cryptococcus meningitis as it is observed to influence mechanisms that inhibited cryptococcal fungal replication among Cryptococcus-infected macrophages in vitro 92. In mouse models, early preemptive use of IL-12 as an adjuvant promoted survival of mice in early use after cryptococcal fungal 92. Whereas the late treatment of mice with IL-12 after the establishment of cryptococcal infection resulted in more mice dying from fungal infection-attributable deaths ⁹². In the current study, IL-12p70 was elevated among female survivors but not males. In the CNS IL-12 is produced by dendritic cells, and is observed to regulate T cell, and NK cell function, and influence the differentiation of the Th1 cellular phenotype 93. With the prominence of T cells and B cells, in the CSF with cryptococcal meningitis ^{19,20}, increased IL-12p70 shading into the CSF can enhance fungal-specific immunocytes activation to mediate fungal neuroimmune mechanisms for control and for improved host survival.

The Th17 cytokine, IL17A, modulated through RORyt regulatory pathway was observed to work in tandem with Th1-modulated cytokines to regulate neuroimmune responses induced to CNS infections ⁹⁴. In particular, IL-17A activates Th17 immunocytes in response to tissue-resident infection. In cryptococcal model infection, IL-17 promoted the development of majority giants cryptococcal cells that have limited ability to cross the blood-brain barrier, leading to localized cryptococcal fungal infection with limited spread to the brain parenchyma where it would cause lethal disease 65,95. Among females, IL-17A was upregulated among those with better survival outcomes. Other Th1 cytokines upregulated among females survivors included IFN-γ, TNF-α and their immune activating factors, CD40 ligand that was demonstrated to facilitate the formation of reactive phagosomes, activation of reactive oxygen and nitrogen species that mediate endogenous killing mechanisms of Cryptococci ingesting macrophages ^{65,95}. Collectively, these immune activating complementary factors, were each increased with increased survival among females. And in the aggregate, these novel findings (reported for the very first in the setting of CM gender-specific survival), drive the question as to how these results may be harnessed for targeted gender-specific therapy to optimize survival where fatal outcomes seem to be propagated by immune-mediated mechanisms that appear to operate independent of the fungal burden, clinical presentation, and current antifungal therapy.

5 **CONCLUSION**

380

381 382

383

384

385

386

387

388 389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407 408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

Survival from HIV-associated CM remains significantly lower in females. We found novel distinctive and divergent intragender-associated CSF cytokine signatures at the time of clinical presentation that was independent of the baseline fungal burden and clinical features. Among females, increased concentration of CCL11, CXCL10, and T cell subset associated cytokines mediating the Th1 and th17 fungal immunopathogenesis pathways to be divergently augmented with female survival but not in males. However, among males, low levels of the neutrophil-activating chemokines IL-8 and the pleiotropic cytokine, IL-15 potentially fashion antifungal regulation neuroimmune milieu, distinctively expressed with improved male survival but not in females. Increased expression of IL-10 and PD-L1 regulatory mechanisms accompany improved survival in both genders identifying common features of a successful CSF profile. The elevated induction of CCL11, CXCL10, IL-17A, and IL-12p70 neuroimmune cytokine signature by female intragender-specific survival in the CSF and their strong positive correlation to IL-10 and PD-L1 highlight the interdependence of these responses in shaping immune homeostasis and survival associated-neuroimmune modulating milieu. These key observations reveal promising signals to consider the impact of more robust responses in females,

- 427 particularly T cell-dependent (CXCL10, Th1/Th17 cytokines), and lower myeloid responses in males
- (e.g., IL-15 and IL-8) and their regulators in controlling outcomes. This data point to the potential 428
- 429 neuroimmune mechanistic targets which could be modified to improve treatment and clinical outcomes
- 430 in those with reversible deaths with immune-based combination antifungal therapy.

6 **LIMITATIONS**

431

432

433

434

435

436 437

438

439

440

441 442

443

444

445

446

447

448

449

450

451

452

453

454

One limitation is that the cross-sectional, exploratory study design generated data could not explain marker and clinical variations after the baseline and prior to death outcome or censor, which might be key to explaining the factors that underlie the observed gender-survival subjective mechanisms. The differential of myeloid vs. lymphoid white cells in the CSF compartment was largely unavailable. The limitations of our interpretations of the baseline cross-sectional findings could be enhanced with longitudinal data to appropriately capture and model changes in the immune profile from diagnosis to eventual survival or death.

CONFLICT OF INTEREST

The authors conformed to the International Committee of Medical Journal Editors (ICMJE) article publication criteria. The authors declared no conflict of interest. Study participants or funders had no role in the design, data curation, or intention to publish. Part of this work was presented in an accepted abstract and poster at the Conference on Retroviruses and Opportunistic Infections (CROI) at Seattle Convention Center, Seattle, Washington, 19-22 February 2023 and was published online on CROI website ⁹⁶. SO was a doctoral fellow and the examined thesis abstract was published online by the Makerere University Online Library as a requirement degree award ⁹⁷.

AUTHOR CONTRIBUTION 8

SO, EO, DBM, ENJ, YCM, DRB, JR, OOJ, HK, BB, and FB, conceptualized the study, framed the hypothesis, and edited the manuscript, SO, YCM, DRB, JR, DBM, and ENJ sourced for funding, designed experiments, guided data analysis, and drafted the manuscript. SO, performed statistical data analysis, compiled the results, put together the first drafted manuscript, and managed the review and publication process. The authors read and approved the final version of the manuscript for online publication.

9 **FUNDING**

455 This work was supported in part by funding from the National Institutes of Health and the 456 National Institute of Allergy and Infectious Diseases R01 AI078934, U01 AI089244, R21 NS065713, 457 R01 AI108479, and T32 AI055433 grants to DBM and DRB; R01 AI108479 grant to JR and R01 458 AI108479 funding to ENJ. National Institute of Neurologic Diseases and Stroke R01 NS086312, R25 459 TW009345, and K24 AI096925 grant to JR. Fogarty International Center D43 TW009771 grant to 460 YCM and R01 NS086312 grant to RJ. GlaxoSmithKline Trust in Science Africa grant COL 100044928 461 grant to SO. DELTAS Africa Initiative DEL-15-011 grant to THRiVE-2, DBM. Wellcome Trust grants 462 107742/Z/15/Z grant to DBM. Veterans Affairs Research Service I01CX001464 grant to ENJ. The 463 Wellcome Trust Training Health Researchers into Vocational Excellence (THRiVE) in East Africa, 464 087540 grant to DBM. United Kingdom Medical Research Council/Wellcome Trust/Department for 465 International Development (MRC MR/M007413/1 grant to JR and the Grand Challenges Canada S4-466 0296-01 grant to JR. Funding agencies had no role in study design, data collection, data analysis plan, 467 preparation of the manuscript, or in the decision to publish.

10 **ACKNOWLEDGEMENTS**

468

469

470

471 472

473

474

475

476

477

478

479

480 481

482

483

484

485

486

487

488 489

490

491

492

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

511

We appreciate the study participants for their involvement in the parent study. We thank the ASTRO trial team for the clinical management of patients and for data collection including Abdu Musubire, Lilian Tugume, Jane Francis Ndyetukira, Cynthia Ahimbisibwe, Florence Kugonza, Alisat Sadiq, Radha Rajasingham, Catherine Nanteza, Kiiza Tadeo Kandole, and Darlisha Williams, Edward Mpoza, Fiona Cresswell, Andrew Akampurira, Apio Alison, Caleb Skipper, Kenneth Ssebambulidde, and Mahsa Abassi. We thank the institutional contribution from Infectious Diseases Institute from Bosco Kafufu, Andrew Kambugu. We thank the PhD program mentorship support received from; Infectious Diseases Institute Capacity Building Unit especially from Barbara D. Castelnuovo, Aidah Nanvuma, Stephen Okoboi, and the Statistics unit, especially from Agnes Kiragga. John Hopkins University, School of Medicine and Bloomberg School of Public Health, Department of Molecular Microbiology, and Immunology, especially from Robert R. Bollinger and Arturo Casadevall. University of Colorado, Denver, Anschutz Medical Campus Aurora, Division of Infectious Disease, Department of Medicine and Veteran Affairs Research Services especially from Brent Palmer, Tina Powell, and Jeremy Rakhola. We thank the statistical data analysis mentorship received from the University of Minnesota, especially from Ananta S. Bangdiwala and Kathy Hullsiek Huppler.

11 ETHICAL CONSIDERATIONS

Participants provided prospective informed written and signed consent and storage consent for specimen use in future studies. Makerere University Higher Degrees Research and Ethics Committee of the School of Biomedical Sciences granted a waiver of informed consent and ethical approvals to analyze the data. The protocol was registered and approved by the National Council of Science and Technology. The parent clinical trial was approved by the National Drug Authority and by the Uganda National Council for Science and Technology. The patient's identifiers were alphanumeric coded and could not identify those patients during the data search.

12 CONTRIBUTIONS TO THE FIELD

The study involved a large sample size with equal ratios between comparative variables that give strong confidence to weighted treatment outcome predictors of HIV-associated cryptococcal meningitis. We discovered the critical role of biological gender in the assessment of survival among patients with HIV-associated cryptococcal meningitis with discrepant bias in women's poor survival. And that immune response differs within gender-specific survival. Together we highlighted the potential role of neuroimmune mechanisms in contributing to the differences in biological gender in survival. The observed immune mechanism illustrates the potential ability of the underlying stimulus in advancing immune-based treatment to work in synergy to improve the efficacy of antifungal drugs to improve survival among preventable deaths.

Interim, we propose close immune monitoring of CCL11/Eotaxin, CXCL10/IP-10, IL-12p70, and IL-17A as key indicators of the beneficial Th1 neuroinflammatory cytokine milieu among HIV and cryptococcal meningitis diagnosed women. We recommended mechanisms to augment CCL11/Eotaxin, CXCL10/IP-10, IL-12p70, and IL-17A cytokine deficient among women in addition to interventions to holistically refurbish the dysregulated or exhausted immune response among those co-infected in an attempt to significantly improve women's survival outcome. We propose close monitoring of IL-15, IL-8/CXCL8 together with IL-10 and PD-L1/B7-H1 dysregulation as key indicators of men's poor survival leading pathway. We recommend mechanisms to restore IL-15 and IL-8/CXCL8, IL-10, and PD-L1/B7-H1 checkpoint responses to improve men's survival outcomes. It is plausible that switching the CCL11/Eotaxin and CXCL10/IP-10 chemokine balance in later stages

- 512 of disease progression to a potentially myeloid pathway can lead to a significant self-reliant neuro-
- 513 injury inflicting pathway leading to poor survival outcomes.

514 13 REFERENCES

- 515 1. Wake RM, Govender NP, Omar T, et al. Cryptococcal-related mortality despite fluconazole
- 516 preemptive treatment in a cryptococcal antigen screen-and-treat program. Clinical Infectious
- 517 Diseases. 2020;70(8):1683-1690. doi:10.1093/cid/ciz485
- 518 2. Rhein J, Huppler Hullsiek K, Tugume L, et al. Adjunctive sertraline for HIV-associated
- 519 cryptococcal meningitis: a randomised, placebo-controlled, double-blind phase 3 trial. The Lancet
- 520 Infectious diseases. 2019;19(8):843-851. doi:10.1016/S1473-3099(19)30127-6
- 521 3. Hakyemez IN, Erdem H, Beraud G, et al. Prediction of unfavorable outcomes in cryptococcal
- 522 meningitis: results of the multicenter Infectious Diseases International Research Initiative (ID-
- 523 IRI) cryptococcal meningitis study. European Journal of Clinical Microbiology and Infectious
- 524 Diseases. 2018;37(7):1231-1240. doi:10.1007/s10096-017-3142-1
- 525 4. Tenforde MW, Jarvis JN. HIV-associated cryptococcal meningitis: ongoing challenges and new
- 526 opportunities. The Lancet Infectious Diseases. 2019;19(8):793-794. doi:10.1016/S1473-
- 527 3099(19)30295-6
- 528 5. Stott KE, Loyse A, Jarvis JN, et al. Cryptococcal meningoencephalitis: time for action. The Lancet
- 529 Infectious Diseases. 2021;21(9):e259-e271. doi:10.1016/S1473-3099(20)30771-4
- 530 6. Boulware DR, von Hohenberg M, Rolfes MA, et al. Human immune response varies by the degree
- 531 of relative cryptococcal antigen shedding. Open Forum Infectious Diseases. 2016;3(1):1-7.
- 532 doi:10.1093/ofid/ofv194
- 533 7. Stadelman AM, Ssebambulidde K, Tugume L, et al. Impact of biological sex on cryptococcal
- 534 meningitis mortality in Uganda and South Africa. Medical Mycology. 2021;59(7):712-719.
- 535 doi:10.1093/mmy/myaa108
- 536 8. Rajasingham R, Smith RM, Park BJ, et al. Global burden of disease of HIV-associated
- 537 cryptococcal meningitis: an updated analysis. The Lancet Infectious diseases. 2017;17(8):873-
- 881. doi:10.1016/S1473-3099(17)30243-8 538
- 539 9. Boulware DR, Meya DB, Muzoora C, et al. Timing of Antiretroviral Therapy after Diagnosis of
- 540 Cryptococcal Meningitis. New England Journal of Medicine. 2014;370(26):2487-2498.
- 541 doi:10.1056/nejmoa1312884
- 542 Kambugu A, Meya DB, Rhein J, et al. Outcomes of cryptococcal meningitis in Uganda before
- 543 and after the availability of highly active antiretroviral therapy. Clinical Infectious Diseases.
- 544 2008;46(11):1694-1701. doi:10.1086/587667
- 545 11. Casadevall A, Pirofski L anne. The damage-response framework of microbial pathogenesis.
- 546 Nature reviews Microbiology. 2003;1(1):17-24. doi:10.1038/nrmicro732

- 547 12. Casadevall A, Pirofski LA. Host-pathogen interactions: Basic concepts of microbial
- commensalism, colonization, infection, and disease. Infection and Immunity. 2000;68(12):6511-548
- 549 6518. doi:10.1128/IAI.68.12.6511-6518.2000
- 550 13. Nielsen K, Cox GM, Litvintseva AP, et al. Cryptococcus neoformans α strains preferentially
- 551 disseminate to the central nervous system during coinfection. Infection and Immunity.
- 552 2005;73(8):4922-4933. doi:10.1128/IAI.73.8.4922-4933.2005
- 553 Santiago-Tirado FH, Onken MD, Cooper JA, Klein RS, Doering TL. Trojan horse transit
- 554 contributes to blood-brain barrier crossing of a eukaryotic pathogen. mBio. 2017;8(1).
- 555 doi:10.1128/mBio.02183-16
- 556 15. Okurut S, Boulware DR, Olobo J, Meya DB. Landmark clinical observations and
- 557 immunopathogenesis pathways linked to HIV and Cryptococcus fatal central nervous system co-
- 558 infection. Mycoses. 2020;63(8):840-853. doi:10.1111/myc.13122
- 559 16. Elsegeiny W, Marr KA, Williamson PR. Immunology of Cryptococcal Infections: Developing a
- 560 Frontiers Rational Approach to Patient Therapy. in immunology. 2018;9:651.
- 561 doi:10.3389/fimmu.2018.00651
- 17. Chang CC, Omarjee S, Lim A, et al. Chemokine levels and chemokine receptor expression in the 562
- 563 blood and the cerebrospinal fluid of HIV-infected patients with cryptococcal meningitis and
- 564 cryptococcosis- Associated immune reconstitution inflammatory syndrome. Journal of Infectious
- 565 Diseases. 2013;208(10):1604-1612. doi:10.1093/infdis/jit388
- 566 Perera PY, Lichy JH, Waldmann TA, Perera LP. The role of interleukin-15 in inflammation and
- 567 immune responses to infection: Implications for its therapeutic use. Microbes and Infection.
- 568 2012;14(3):247-261. doi:10.1016/j.micinf.2011.10.006
- 569 19. Meya DB, Okurut S, Zziwa G, et al. Cellular immune activation in cerebrospinal fluid from
- 570 ugandans with cryptococcal meningitis and immune reconstitution inflammatory syndrome.
- 571 Journal of Infectious Diseases. 2015;211(10):1597-1606. doi:10.1093/infdis/jiu664
- 572 20. Okurut S, Meya DB, Bwanga F, et al. B cell Compartmentalization in Blood and Cerebrospinal
- 573 Fluid of HIV-Infected Ugandans with Cryptococcal Meningitis. Noverr MC, ed. Infection and
- 574 Immunity. 2020;88(3):1-14. doi:10.1128/IAI.00779-19
- 575 21. Esher SK, Zaragoza O, Alspaugh JA. Cryptococcal pathogenic mechanisms: A dangerous trip
- 576 from the environment to the brain. Memorias do Instituto Oswaldo Cruz. 2018;113(7):1-15.
- 577 doi:10.1590/0074-02760180057
- 578 Mora DJ, Fortunato LR, Andrade-Silva LE, et al. Cytokine profiles at admission can be related
- 579 to outcome in AIDS patients with cryptococcal meningitis. PLoS ONE. 2015;10(3):1-17.
- 580 doi:10.1371/journal.pone.0120297
- 581 Xu XG, Pan WH, Bi XL, et al. Comparison of clinical features in patients with persistent and
- 582 nonpersistent cryptococcal meningitis: Twelve years of clinical experience in four centers in
- 583 china. CNS Neuroscience and Therapeutics. 2013;19(8):625-631. doi:10.1111/cns.12135

- 584 24. Rhein J, Hullsiek KH, Tugume L, et al. HHS Public Access. 2020;19(8):843-851. doi:10.1016/S1473-3099(19)30127-6.Adjunctive 585
- 586 Rolfes MA, Hullsiek KH, Rhein J, et al. The effect of therapeutic lumbar punctures on acute mortality from cryptococcal meningitis. Clinical Infectious Diseases. 2014;59(11):1607-1614. 587 588 doi:10.1093/cid/ciu596
- 589 26. Jarvis JN, Bicanic T, Loyse A, et al. Determinants of mortality in a combined cohort of 501 590 patients with HIV-associated cryptococcal meningitis: Implications for improving outcomes. Clinical Infectious Diseases. 2014;58(5):736-745. doi:10.1093/cid/cit794 591
- 592 27. Lawrence DS, Leeme T, Mosepele M, Harrison TS, Seeley J, Jarvis JN. Equity in clinical trials 593 for hiv-associated cryptococcal meningitis: A systematic review of global representation and 594 inclusion of patients and researchers. PLoS Neglected Tropical Diseases. 2021;15(5):1-19. doi:10.1371/journal.pntd.0009376 595
- 596 28. Pappas PG, Bustamante B, Ticona E, et al. Recombinant Interferon-γ1b as Adjunctive Therapy 597 for AIDS-Related Acute Cryptococcal Meningitis. The Journal of Infectious Diseases. 598 2004;189(12):2185-2191. doi:10.1086/420829
- 599 Boulware DR, Bonham SC, Meya DB, et al. Paucity of initial cerebrospinal fluid inflammation 600 in cryptococcal meningitis is associated with subsequent immune reconstitution inflammatory syndrome. The Journal of infectious diseases. 2010;202(6):962-970. doi:10.1086/655785 601
- 30. Rajasingham R, Rhein J, Klammer K, et al. Epidemiology of meningitis in an HIV-infected 602 603 Ugandan cohort. American Journal of Tropical Medicine and Hygiene. 2015;92(2):274-279. 604 doi:10.4269/ajtmh.14-0452
- 605 31. George IA, Santos CAQQ, Olsen MA, Powderly WG. Epidemiology of cryptococcosis and 606 cryptococcal meningitis in a large retrospective cohort of patients after solid organ 607 transplantation. Open Forum Infectious Diseases. 2017;4(1):1-7. doi:10.1093/ofid/ofx004
- 608 32. Rhein J, Morawski BM, Hullsiek KH, et al. Associated Cryptococcal Meningitis: an open-label 609 dose-ranging study. Lancet Infect Dis. 2017;16(7):809-818. doi:10.1016/S1473-3099(16)00074-610 8.Efficacy
- 611 Kashef Hamadani BH, Franco-Paredes C, McCollister B, Shapiro L, Beckham JD, Henao-612 Martínez AF. Cryptococcosis and cryptococcal meningitis: New predictors and clinical outcomes States academic 613 United medical centre. Mycoses. 2018;61(5):314-320. at 614 doi:10.1111/myc.12742
- Meya DB, Kiragga AN, Nalintya E, ... Reflexive laboratory-based cryptococcal antigen screening 615 616 and preemptive fluconazole therapy for cryptococcal antigenemia in HIV-infected individuals 617 with Journal of acquired 2019;80(2):182-189.
- 618 Pastick KA, Bangdiwala AS, Abassi M, et al. Seizures in Human Immunodeficiency Virus-619 Associated Cryptococcal Meningitis: Predictors and Outcomes. *Open Forum Infectious Diseases*. 620 2019;6(11):1-7. doi:10.1093/ofid/ofz478

- 621 36. Lakoh S, Rickman H, Sesay M, et al. Prevalence and mortality of cryptococcal disease in adults
- 622 with advanced HIV in an urban tertiary hospital in Sierra Leone: A prospective study. BMC
- 623 *Infectious Diseases*. 2020;20(1):1-7. doi:10.1186/s12879-020-4862-x
- 624 37. Marr KA, Sun Y, Spec A, et al. A multicenter, longitudinal cohort study of cryptococcosis in
- 625 human immunodeficiency virus-negative people in the United States. Clinical Infectious
- 626 Diseases. 2020;70(2):252-261. doi:10.1093/cid/ciz193
- 627 38. Lee WJ, Ryu YJ, Moon J, et al. Enlarged periventricular space and periventricular lesion
- 628 extension on baseline brain MRI predicts poor neurological outcomes in cryptococcus
- 629 meningoencephalitis. Scientific Reports. 2021;11(1):1-11. doi:10.1038/s41598-021-85998-6
- 630 39. Kalata N, Ellis J, Kanyama C, et al. Short-term Mortality outcomes of HIV-Associated
- 631 cryptococcal meningitis in antiretroviral therapy-naïve and -experienced patients in sub-saharan
- 632 Africa. Open Forum Infectious Diseases. 2021;8(10):1-5. doi:10.1093/ofid/ofab397
- 40. Mansoor A e.Rehman, Thompson J, Sarwari AR. Delays in lumbar puncture are independently 633
- 634 associated with mortality in cryptococcal meningitis: a nationwide study. Infectious Diseases.
- 2021;53(5):361-369. doi:10.1080/23744235.2021.1889656 635
- 41. Deiss R, Loreti CV, Gutierrez AG, et al. High burden of cryptococcal antigenemia and meningitis 636
- 637 among patients presenting at an emergency department in Maputo, Mozambique. PLoS ONE.
- 2021;16(4 April):1-11. doi:10.1371/journal.pone.0250195 638
- 639 42. Zhao T, Xu XL, Nie JM, et al. Establishment of a novel scoring model for mortality risk prediction
- 640 in HIV-infected patients with cryptococcal meningitis. BMC Infectious Diseases. 2021;21(1):1-
- 641 10. doi:10.1186/s12879-021-06417-9
- 642 43. Jarvis JN, Lawrence DS, Meya DB, et al. Single-Dose Liposomal Amphotericin B Treatment for
- 643 Cryptococcal Meningitis. New England Journal of Medicine. 2022;386(12):1109-1120.
- 644 doi:10.1056/nejmoa2111904
- 645 44. Baldassarre R, Mdodo R, Omonge E, et al. Mortality after clinical management of aids-associated
- 646 cryptococcal meningitis in Kenya. East African Medical Journal. 2014;91(5):145-151.
- 647 45. Furman D, Hejblum BP, Simon N, et al. Systems analysis of sex differences reveals an
- 648 immunosuppressive role for testosterone in the response to influenza vaccination. *Proceedings of*
- 649 the National Academy of Sciences of the United States of America. 2014;111(2):869-874.
- 650 doi:10.1073/pnas.1321060111
- 651 46. Fink AL, Engle K, Ursin RL, Tang WY, Klein SL. Biological sex affects vaccine efficacy and
- 652 protection against influenza in mice. Proceedings of the National Academy of Sciences of the
- 653 United States of America. 2018;115(49):12477-12482. doi:10.1073/pnas.1805268115
- 654 Garelnabi M, Taylor-Smith LM, Bielska E, Hall RA, Stones D, May RC. Quantifying donor-to-
- 655 donor variation in macrophage responses to the human fungal pathogen Cryptococcus
- 656 neoformans. *PLoS ONE*. 2018;13(3):1-12. doi:10.1371/journal.pone.0194615

- 657 48. Rhein J, Morawski BM, Hullsiek KH, et al. Efficacy of adjunctive sertraline for the treatment of 658 HIV-associated cryptococcal meningitis: an open-label dose-ranging study. The Lancet Infectious 659 diseases. 2016;16(7):809-818. doi:10.1016/S1473-3099(16)00074-8
- 660 49. Vidal JE, Toniolo C, Paulino A, et al. Performance of cryptococcal antigen lateral flow assay in 661 serum, cerebrospinal fluid, whole blood, and urine in HIV-infected patients with culture-proven 662 cryptococcal meningitis admitted at a Brazilian referral center. Revista do Instituto de Medicina 663 Tropical de Sao Paulo. 2018;60:e1-e1. doi:10.1590/s1678-9946201860001
- 664 50. Rajasingham R, Wake RM, Beyene T, Katende A, Letang E, Boulware DR. Cryptococcal 665 Meningitis Diagnostics and Screening in the Era of Point-of-Care Laboratory Testing. Journal of 666 clinical microbiology. 2019;57(1):e01238-18. doi:10.1128/JCM.01238-18
- 667 51. Vazirinejad R, Ahmadi Z, Arababadi MK, Hassanshahi G, Kennedy D. The biological functions, 668 structure and sources of CXCL10 and its outstanding part in the pathophysiology of multiple 669 sclerosis. NeuroImmunoModulation. 2014;21(6):322-330. doi:10.1159/000357780
- Michlmayr D, McKimmie CS. Role of CXCL10 in central nervous system inflammation. 670 International Journal of Interferon, Cytokine and Mediator Research. 2014;6(1):1-18. 671 672 doi:10.2147/IJICMR.S35953
- 673 53. Teixeira AL, Gama CS, Rocha NP, Teixeira MM. Revisiting the role of eotaxin-1/CCL11 in 674 psychiatric disorders. Frontiers in Psychiatry. 2018;9(JUN):1-6. doi:10.3389/fpsyt.2018.00241
- 54. Parajuli B, Horiuchi H, Mizuno T, Takeuchi H, Suzumura A. CCL11 enhances excitotoxic 675 676 neuronal death by producing reactive oxygen species in microglia. Glia. 2015;63(12):2274-2284. 677 doi:10.1002/glia.22892
- 678 55. Mamik MK, Ghorpade A. Chemokine CXCL8 promotes HIV-1 replication in human monocyte-679 derived macrophages and primary microglia via nuclear factor-κB pathway. PLoS ONE. 680 2014;9(3):1-13. doi:10.1371/journal.pone.0092145
- 56. Chauhan P, Lokensgard JR. Glial cell expression of PD-L1. *International Journal of Molecular* 681 682 Sciences. 2019;20(7):1-12. doi:10.3390/ijms20071677
- 57. Burmeister AR, Marriott I. The interleukin-10 family of cytokines and their role in the CNS. 683 684 Frontiers in Cellular Neuroscience. 2018;12(November):1-13. doi:10.3389/fncel.2018.00458
- 685 58. Ringnér M. What is principal component analysis? *Nature Biotechnology*. 2008;26(3):303-304. 686 doi:10.1038/nbt0308-303
- 59. Giuliani A. The application of principal component analysis to drug discovery and biomedical 687 data. Drug Discovery Today. 2017;22(7):1069-1076. doi:10.1016/j.drudis.2017.01.005 688
- 689 60. Scriven JE, Graham LM, Schutz C, et al. A glucuronoxylomannan-associated immune signature, 690 characterized by monocyte deactivation and an increased interleukin 10 level, is a predictor of
- 691 death in cryptococcal meningitis. Journal of Infectious Diseases. 2016;213(11):1725-1734.
- 692 doi:10.1093/infdis/jiw007

- 693 61. Gerstein AC, Jackson KM, McDonald TR, et al. Identification of pathogen genomic differences
- 694 that impact human immune response and disease during cryptococcus neoformans infection.
- 695 *mBio*. 2019;10(4):1-22. doi:10.1128/mBio.01440-19
- 696 Traino K, Snow J, Ham L, et al. HIV-Negative Cryptococcal Meningoencephalitis Results in a
- 697 Persistent Frontal-Subcortical Syndrome. Scientific Reports. 2019;9(1):1-9. doi:10.1038/s41598-
- 698 019-54876-7
- 699 63. Vanherp L, Poelmans J, Weerasekera A, et al. Trehalose as quantitative biomarker for in vivo
- 700 diagnosis and treatment follow-up in cryptococcomas. Translational research: the journal of
- 701 laboratory and clinical medicine. 2021;230:111-122. doi:10.1016/j.trs1.2020.11.001
- 702 64. Leite AGB, Vidal JE, Bonasser Filho F, Nogueira RS, Oliveira ACP de. Cerebral infarction
- 703 related to cryptococcal meningitis in an HIV-infected patient: case report and literature review.
- 704 The Brazilian journal of infectious diseases: an official publication of the Brazilian Society of
- 705 Infectious Diseases. 2004;8(2):175-179. doi:10.1590/S1413-86702004000200008
- 706 Orsini J, Blaak C, Mahmoud D, Young-Gwang J. Massive cerebral edema resulting in brain death
- 707 as a complication of cryptococcus neoformans meningitis. Journal of Community Hospital
- 708 Internal Medicine Perspectives. 2015;5(1):3-6. doi:10.3402/jchimp.v5.26098
- 709 66. Jarvis JN, Meintjes G, Bicanic T, et al. Cerebrospinal Fluid Cytokine Profiles Predict Risk of
- 710 Early Mortality and Immune Reconstitution Inflammatory Syndrome in HIV-Associated
- 711 Cryptococcal Meningitis. PLoS Pathogens. 2015;11(4):1-17. doi:10.1371/journal.ppat.1004754
- 712 Jarvis JN, Casazza JP, Stone HH, et al. The phenotype of the cryptococcus-specific CD4+
- 713 memory T-cell response is associated with disease severity and outcome in HIV-associated
- 714 cryptococcal meningitis. Journal of Infectious Diseases. 2013;207(12):1817-1828.
- 715 doi:10.1093/infdis/jit099
- 716 Qiao X, Zhang W, Zhao W. Role of CXCL10 in Spinal Cord Injury. Int J Med Sci.
- 717 2022;19(14):2058-2070. doi:10.7150/ijms.76694
- 718 Teixeira AL, Gama CS, Rocha NP, Teixeira MM. Revisiting the Role of Eotaxin-1/CCL11 in
- 719 Psychiatric Disorders. Front Psychiatry. 2018;9:241. doi:10.3389/fpsyt.2018.00241
- 720 Okafor EC, Hullsiek KH, Williams DA, et al. Correlation between blood and CSF compartment
- 721 cytokines and chemokines in subjects with cryptococcal meningitis. *Mediators of Inflammation*.
- 722 2020;2020. doi:10.1155/2020/8818044
- 723 71. Boulware DR, Meya DB, Bergemann TL, et al. Clinical features and serum biomarkers in HIV
- 724 immune reconstitution inflammatory syndrome after cryptococcal meningitis: A prospective
- 725 cohort study. PLoS Medicine. 2010;7(12):1-14. doi:10.1371/journal.pmed.1000384
- 726 Lobo-Silva D, Carriche GM, Castro AG, Roque S, Saraiva M. Balancing the immune response in
- 727 the brain: IL-10 and its regulation. Journal of Neuroinflammation. 2016;13(1):1-10.
- 728 doi:10.1186/s12974-016-0763-8
- 729 Wake RM, Govender NP, Omar T, et al. Cryptococcal-related mortality despite fluconazole pre-
- 730 emptive treatment in a cryptococcal antigen (CrAg) screen-and-treat programme. Clinical

- 731 infectious diseases: an official publication of the Infectious Diseases Society of America.
- 732 Published online June 2019. doi:10.1093/cid/ciz485
- 733 Meya D, Okurut S, Zziwa G, et al. Monocyte Phenotype and IFN-γ-Inducible Cytokine Responses
- 734 Are Associated with Cryptococcal Immune Reconstitution Inflammatory Syndrome. Journal of
- 735 Fungi. 2017;3(2):28. doi:10.3390/jof3020028
- 736 75. Meya DB, Okurut S, Zziwa G, Cose S, Boulware DR, Janoff EN. HIV-Associated Cryptococcal
- 737 Immune Reconstitution Inflammatory Syndrome Is Associated with Aberrant T Cell Function
- 738 and Increased Cytokine Responses. Journal of fungi (Basel, Switzerland). 2019;5(2):42.
- 739 doi:10.3390/jof5020042
- 740 76. Bickel M. The role of interleukin-8 in inflammation and mechanisms of regulation. *Journal of* 741 periodontology. 1993;64(5 Suppl):456-460.
- 742 77. Ehrlich LC, Hu S, Sheng WS, et al. Cytokine regulation of human microglial cell IL-8 production. 743 Journal of immunology (Baltimore, Md: 1950). 1998;160(4):1944-1948.
- 744 78. Rosales C. Neutrophil: A cell with many roles in inflammation or several cell types? Frontiers in 745 Physiology. 2018;9(FEB):1-17. doi:10.3389/fphys.2018.00113
- 79. Guimarães-Costa AB, Nascimento MTC, Wardini AB, Pinto-Da-Silva LH, Saraiva EM. ETosis: 746
- 747 A microbicidal mechanism beyond cell death. Journal of Parasitology Research.
- 748 2012;2012(Table 1). doi:10.1155/2012/929743
- 749 80. Musubire AK, Meya DB, Rhein J, et al. Blood neutrophil counts in HIV-infected patients with
- 750 cryptococcal meningitis: Association with mortality. *PloS one*. 2018;13(12):e0209337-e0209337.
- 751 doi:10.1371/journal.pone.0209337
- 752 81. Grahl N, Shepardson KM, Chung D, Cramer RA. Hypoxia and fungal pathogenesis: To air or not to air? Eukaryotic Cell. 2012;11(5):560-570. doi:10.1128/EC.00031-12 753
- 82. Diehl JW, Hullsiek KH, Okirwoth M, et al. Cerebral Oximetry for Detecting High-mortality Risk 754
- 755 Patients with Cryptococcal Meningitis. Published online 2017:1-7. doi:10.1093/ofid/ofy105
- 756 Shimoda Y, Ohtomo S, Arai H, Ohtoh T, Tominaga T. Subarachnoid small vein occlusion due to
- 757 inflammatory fibrosis—a possible mechanism for cerebellar infarction in cryptococcal
- 758 meningoencephalitis: a case report. BMC Neurology. 2017;17(1):157. doi:10.1186/s12883-017-
- 759 0934-y
- 760 84. Hung CW, Chang WN, Kung CT, et al. Predictors and long-term outcome of seizures in human
- 761 immuno-deficiency virus (HIV)-negative cryptococcal meningitis. BMC Neurology.
- 762 2014;14(1):1-8. doi:10.1186/s12883-014-0208-x
- 763 85. Saito T, Saido TC. Neuroinflammation in mouse models of Alzheimer's disease. Clinical and
- 764 Experimental Neuroimmunology. 2018;9(4):211-218. doi:10.1111/cen3.12475
- 765 86. Lu Y, Ma C, Chen R, et al. Development and validation of a new scoring system for the early
- 766 diagnosis of tuberculous meningitis in adults. Diagnostic Microbiology and Infectious Disease.
- 767 2021;101(2):115393. doi:10.1016/j.diagmicrobio.2021.115393

- 768 87. D'Inzeo T, Menchinelli G, De Angelis G, et al. Implementation of the eazyplex® CSF direct 769 panel assay for rapid laboratory diagnosis of bacterial meningitis: 32-month experience at a 770 tertiary care university hospital. European Journal of Clinical Microbiology and Infectious 771 Diseases. 2020;39(10):1845-1853. doi:10.1007/s10096-020-03909-5
- 772 88. Sokol CL, Luster AD. The chemokine system in innate immunity. Cold Spring Harbor 773 Perspectives in Biology. 2015;7(5):1-20. doi:10.1101/cshperspect.a016303
- 774 89. Veenstra M, León-Rivera R, Li M, Gama L, Clements JE, Berman JW. Mechanisms of CNS viral 775 seeding by HIV+ CD14+ CD16+ monocytes: Establishment and reseeding of viral reservoirs 776 contributing to HIV-associated neurocognitive disorders. mBio.2017;8(5):1-15. 777 doi:10.1128/mBio.01280-17
- 778 90. Persidsky Y, Poluektova L. Immune Privilege and HIV-1 Persistence in the CNS. Vol 213.; 779 2006:180-194. doi:10.1111/j.1600-065X.2006.00440.x
- 780 91. Panackal AA, Wuest SC, Lin YC, et al. Paradoxical Immune Responses in Non-HIV 781 Cryptococcal Meningitis. PLoS Pathogens. 2015;11(5):1-27. doi:10.1371/journal.ppat.1004884
- 92. Kawakami K, Qureshi MH, Koguchi Y, Nakajima K, Saito A. Differential effect of Cryptococcus 782 783 neoformans on the production of IL-12p40 and IL-10 by murine macrophages stimulated with 784 lipopolysaccharide and gamma interferon. FEMS Microbiology Letters. 1999;175(1):87-94. doi:10.1016/S0378-1097(99)00172-X 785
- 786 93. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. *Nature* Reviews Immunology. 2003;3(2):133-146. doi:10.1038/nri1001 787
- 788 94. Kuwabara T, Ishikawa F, Kondo M, Kakiuchi T. The Role of IL-17 and Related Cytokines in 789 Inflammatory Autoimmune Diseases. Mediators of Inflammation. 2017;2017. 790 doi:10.1155/2017/3908061
- 791 95. Lee SC, Casadevall A, Dickson DW. Immunohistochemical localization of capsular 792 polysaccharide antigen in the central nervous system cells in cryptococcal meningoencephalitis. 793 *The American journal of pathology.* 1996;148(4):1267-1274.
- 794 96. Okurut S, Okafor E, Boulware DR, et al. Okurut, S., Okafor, E., Boulware, RD., Rhein J., 795 Manabe, CY., Olobo OJ., Meya BD., and Janoff, NE., (2023). Divergent neuroimmune signatures 796 and HIV-associated cryptococcal meningitis survival. Abstract and poster retrieved on July 28, 797 2023 **CROI** webseite. 489 ePoster. from 2023;(2023).
- 798 https://www.croiconference.org/abstract/divergent-neuroimmune-signatures-and-hiv-associated-799 cryptococcal-meningitis-survival/
- 800 97. Okurut, S. (2023) B cell responses, immune modulation and survival among patients with HIV-801 associated cryptococcal meningitis. [PhD. Thesis]. [Kampala, Uganda]: Makerere University.

803

14 **TABLES**

806 807

Table 1, Baseline Demographics of People With HIV-Associated cryptococcal meningitis by Gender

Variables	N	Females Median (IQR) or N (%)	N	Men Median (IQR) or N (%)	P- value
Participants, N=419, n (%)		168 (40.1)		251 (59.9)	
Demographics					
Age, years	167	32 (28-38)	246	35 (30-40)	0.004
Weight, Kg	155	50 (47-60)	238	54 (50-60)	0.007
On ART, n (%)	167	73 (48.7)		125 (54.3)	
Duration of ART, days	77	167 (64-1109)	135	231 (29-1095)	
Signs and symptoms					
Headache at presentation, n (%)	168	161 (95.8)	251	240 (95.6)	
Duration of headache, days	161	14 (7-21)	240	14 (7-30)	
Cachexia, n (%)	167	72 (43.1)	246	112 (45.5)	
Photophobia, n (%)	166	57 (34.1)	145	66 (26.8)	

Seizures present, n (%)	168	22 (13.1)	246	42 (17.1)	
Altered mental status, n (%)	167	56 (33.5)	246	96 (39)	
Glasgow Coma Scale <15, n (%)	166	80 (47.9)	246	115 (46.7)	
Systolic blood pressure, mmHg	166	120.0 (105.8-131.3)	242	123.0 (112.8-138.3)	0.007
Diastolic blood pressure mmHg	166	79.5 (69.0-90.0)	242	80.0 (70.0-93.0)	
Blood Clinical analysis	<u>s</u>				
Glucose, mmol/L	75	5.8 (4.9-6.8)	111	5.7 (4.9-6.4)	
White blood cells, x10 ⁹ /L	156	3.5 (2.7-4.9)	226	3.5 (2.5-5.1)	
CD4 T cell counts/μL	162	23 (8-58)	234	15 (5-39)	0.004
CD8 T cell counts/μL	160	334 (168-632)	230	283 (172-481)	
Hemoglobin, g/dL	156	10.8 (9.1-12)	226	12.4 (10.4-13.7)	< 0.001
Platelets, x10 ⁹ /L	156	216 (144-270)	225	179 (128-245)	0.021
CSF Clinical analysis					
Glucose, mmol/L	55	3.3 (2.1-4.4)	78	4.6 (2.3-6)	0.033
Protein mg/dL	140	40 (23-96)	199	58 (25-113)	

White blood cells/μL	160	<5 (<5-34)	241	<5 (<5-45)
Opening pressure, mmH ₂ O	143	270 (180-424)	212	298 (220-427.5)
Cryptococcal culture, Log ₁₀ cfu/mL	152	4.9 (3.3-5.6)	223	4.7 (3.7-5.6)

Statistics: Mann-Whitney U-test, Chi-Square test. Not statistically significant variables had p-value ≥0.05 at a 95% confidence interval. CFU - colony forming units. CSF - cerebrospinal fluid. ART antiretroviral therapy. Normal CSF proteins in adults: 15-60 mg/dL. Normal CSF glucose: 2.5 -4.4 mmol/L.

Table 2, Differences in Baseline Immune Signature in Cerebrospinal Fluid Exudate by Gender Among Patients with HIV-Associated Cryptococcal Meningitis.

818

Variables	Females, Median (IQR)	Men, Median (IQR)	P-value
Participants, N=419	168 (40.1)	251 (59.9)	
Immune checkpoint inl	<u>nibitor</u>		
PD-L1/B7-H1	90.0 (41.0-170.6)	112.5 (53.4-205.9)	0.028
T helper 1 cytokines			
TNF-α	37.4 (11.8-86.3)	49.2 (20.3-109.4)	0.048
IL-2	5.0 (2.1-8.8)	5.1 (2.5-9.0)	
IFN-γ	3.8 (0.4-10.3)	5.2 (0.4-12.9)	
CD40 Ligand/TNFSF5	370.2 (73.1-636.4)	411.1 (188.2-715)	
CCL11/Eotaxin	15.0 (6.2-20.7)	14.5 (7.4-20.2)	
IL-12p70	5.2 (1.4-10.0)	6.0 (1.7-10.4)	
CXCL10/IP-10	2407.0 (1038.0-3037.0)	2394.0 (1161.0-3017.0)	
T helper 2 cytokine			
IL-4	1.2 (0.4-2.2)	1.3 (0.5-2.3)	
IL-13	22.3 (10.9-35.4)	21.9 (10.6-35.0)	
T helper 17 cytokine			

IL-17A	1.6 (0.2-4.1)	2.3 (0.2-5.4)						
T follicular helper cytokines								
IL-10	213.2 (144.7-325.2)	242.8 (161.6-348.3)						
Innate myeloid cytokin	<u>es</u>							
IL-1RA/IL-1F3	4041.0 (1139.0-10005.0)	6142.0 (2582.0-10067.0)	0.001					
IL-15	2.8 (1.8-4.6)	3.6 (2.5-5.2)	0.003					
IL-8/CXCL8	346.5 (148.0-1042.0)	380.4 (135.4-1118.0)						
IL-6	142.4 (44.4-721.3)	209.3 (48.6-1344.0)						

Cerebrospinal fluid cytokine differentiation with gender: Cytokine and chemokine levels were measured in picogram per milliliter (pg/mL). Statistics: Mann-Whitney U-test. The statistically similar variable had a p-value ≥ 0.05 at a 95% confidence interval.

Table 3. Univariate Difference in Baseline Levels of CSF Factors Associated with Gender Survival Among Patients with HIV-Associated CM.

829

Cytokine, Pg/mL	<u>Females</u> Alive Median (IQR)	<u>Females</u> Died Median (IQR)	P- value	Males Alive Median (IQR)	<u>Males</u> Died Median (IQR)	P- value
N	71	79		136	94	
T helper 1 cytoki		19		130	94	
IL-2	6.0	4.3		4.5	5.2	
1L-2	(4.4-10.1)	(2.0-7.7)		(2.3-8.6)	(2.8-10.3)	
IFN-γ	5.2	2.1		3.8	6.0	
11/1 Ν- γ	(0.4-14.0)	(0.3-8.4)		(0.4-10.9)	(0.4-16.2)	
IL-12p70	7.6	3.6	0.018	6.0	6.0	
1L-12p/0	(2.6-11.2)	(0.8-8.4)	0.018	(1.6-10.2)	(2.0-10.8)	
TNF-α	54.1	27.9	0.041	61.1	38.1	
11ν1′-α	(15.8-108.5)	(8.3-69.4)	0.041	(27.4-104.0)	(15.4-115.5)	
CD40-L/	428.1	290.4	0.049	433.7	395.2	
TNFSF5	(115.7-	(65.2-534.7)	0.049	(171.2-710.9)	(188.2-797.4)	
TNIBIS	732.7)	(03.2-334.7)		(1/1.2-/10.7)	(100.2-777.7)	
CCL11/Eotaxin	17.0	12.4	0.001	14.5	14.6	
CCETTLOURIN	(11.4-21.6)	(3.3-18.6)	0.001	(7.2-20.1)	(9.2-20.5)	
CXCL10/-IP-10	2613.0	1590.0	0.001	2515.0	2369.0	
CHCLIO/ II 10	(2071.0-	(497.1-2702.0)	0.001	(1432.0-	(974.1-3068.0)	
	3330.0)	(157.11 2702.0)		3016.0)	(57 1.1 5000.0)	
T helper 2 cytoki	,			2010.0)		
IL-4	1.3	1.1		1.3	1.6	
	(0.6-2.6)	(0.3-2.1)		(0.5-2.5)	(0.7-2.3)	
IL-13	28.7	20.1	0.041	27.6	20.6	0.001
	(14.0-38.1)	(5.9-31.6)		(18.4-37.6)	(4.2-32.5)	
T helper 17 cytol		,		,	,	
IL-17A	2.8	0.9	< 0.001	2.8	2.2	
	(0.9-6.0)	(0.2-3.0)		(0.3 - 5.9)	(0.2-5.1)	
T follicular helpe	er or immune re	egulatory cytokin	<u>e</u>			
IL-10	241.2	184.1	0.009	267.0	212.4	0.002
	(175.7-	(175.7-278.1)		(209.7-374.7)	(134.5-338.8)	
	384.5)					
Innate-like cytok				,		
IL-1RA/IL-1F3	3830.0	3983.0		5361.0	6201.0	
	(12070.0-	(843.1 -		(2329.0-	(2378.0-	
	10005.0)	10011.0)		10032.0)	10078.0)	
IL-6	155.7	123.4		202.4	189.0	
	(36.3-962.1)	(40.6-514.5)		(48.3-1267.0)	(41.6-1305.0)	
IL-8 (CXCL8)	460.0	303.5		329.1	384.9	
	(147.8-	(141.6-916.4)		(162.9-938.3)	(112.4-1153.0)	
YY 1.5	1042.0)	2 -		2.2		0.005
IL-15	2.8	2.7		3.2	4.0	0.002

	(1.8-5.3)	(1.7-4.0)	(2	2.3-4.6)	(2.9-5.9)	
Immune checkp	oint factor					
PD-L1	107.3	72.2		126.9	101.1	
	(44.2-174.9)	(36.0-158.5)	(67	.1-192.0)	(50.5-216.6)	

Cerebrospinal fluid cytokine differentiation with gender-specific survival: Statistics: Mann-Whitney U-test, not statistically significant variables had a p-value ≥0.050 at a 95% confidence interval.

Table 4, Baseline Independent Factors Predicting Intragender 18 Weeks Survival Among Patients with HIV-Associated Cryptococcal Meningitis on Antifungal Therapy.

837

<u>Variables</u> Cytokines, Log ₂ (Pg/mL)	Females Odds ratio estimate (95% CI for profile likelihood)	P-value	Men Odds ratio estimate (95% CI for profile likelihood)	P-value
Survival at 18 weeks, N (%)	71 of 150 (47.3)		136 of 230 (59.1)	0.024
N (range)/model	Survived (n=63 to n=70) Died (n=60 to n=71)		Survived (n=118 to n=131) Died (n=78 to n=91)	
Model 1, survival adjusted	for cytokine			
CCL11/Eotaxin	0.42 (0.20-0.80)	0.014	1.65 (1.00-2.76)	
CXCL10/-IP-10	0.48 (0.27-0.79)	0.006	1.03 (0.76-1.40)	
IL-8/CXCL8	0.93 (0.65-1.31)		1.38 (1.03-1.88)	0.034
IL-15	0.96 (0.57-1.62)		1.88 (1.20-3.04)	0.007
Model 2, survival adjusted	for age, weight, systolic	e blood pr	essure and cytokines	
CCL11/Eotaxin	0.35 (0.16-0.69)	0.005	1.55 (0.94-2.60)	
CXCL10/IP-10	0.55 (0.30-0.96)	0.042	1.00 (0.73-1.37)	
IL-10	2.26 (1.00-5.11)	0.044	0.65 (0.32-1.27)	
IL-15	0.86 (0.48-1.50)		1.63 (1.03-2.64)	0.040

Model 3, survival adjusted for hemoglobin, platelets count, CD4 counts and cytokines									
CD4 T cell counts/ μL	0.99 (0.98-1.00)	0.039	1.00 (0.99-1.01)						
IL-2	1.94 (1.13-3.78)	0.025	0.59 (0.30-1.06)						
IL-10	2.33 (1.04-5.39)	0.038	0.73 (0.34-1.51)						
CCL11/Eotaxin	0.29 (0.12-0.63)	0.004	1.044 (0.970-1.129)						
CXCL10/IP-10	0.45 (0.25-0.76)	0.004	0.98 (0.69-1.38)						
IL-8/CXCL8	0.92 (0.64-1.32)		1.69 (1.17-2.58)	0.009					
IL-15	0.81 (0.43-1.49)		1.79 (1.05-3.20)	0.041					
Hemoglobin, g/dL	0.82 (0.66-1.02)		0.82 (0.70-0.94)	0.006					
Model 4, survival adjusted	for sodium, potassium	and cyto	<u>skines</u>						
CCL11/Eotaxin	0.32 (0.12-0.70)	0.009	1.74 (1.01-3.05)	0.048					
CXCL10/IP-10	0.52 (0.27-0.92)	0.033	1.10 (0.79-1.55)						
IL-8/CXCL8	0.87 (0.59-1.28)		1.41 (1.02-2.00)	0.044					
IL-15	0.89 (0.48-1.66)		2.36 (1.43-4.12)	0.001					
Sodium, mmol/L	0.96 (0.88-1.04)		0.87 (0.93-0.98)	0.011					
Potassium, mmol/L	0.49 (0.24-0.95)	0.044	0.99 (0.62-1.59)						

Multivariate adjusted models of gender-specific associated factors (univariate gender-specific survivalassociated factors in Table 3), were interrogated with statistically different gender-associated

839

840

demographic variables (Table 1). Odds ratios represent the independent likelihood of survival based on levels of the indicated factor with an adjusted multivariate logistic regression model. Statistic: intragender (male or female) multiple logistic regression. Not statistically significant variables had adjusted p-value ≥0.05 at a 95% confidence interval. The main effect of variables on gender survival.

842 843

844

FIGURES

Figure 1




Figure 1. The proportion of cases with HIV-associated CM by gender and of related survival by gender in 21 published case series. These studies include 38,485 cases with 5,834 reported deaths, which accounted for a 15.2% case fatality rate (see Supplementary Table 1 for details and references 7,9,19,26,28-⁴⁴. Bars show median values. 5 studies report survival by gender (4 references and this report; Supplemental Table 1).

Figure 2

Kaplan-Meier: by 18-Weeks Mortality




Figure 2. Survival among people with HIV-associated cryptococcal meningitis. The p-value <0.05 is statistically different.

Figure 3

867

868

869

870

871

872

873 874

875

876

877

878

879

880

881




Figure 3. Projection of cytokine responses on Eigenvector correlation covariates on PC1 and PC 2 (axes) using unsupervised principal component analysis. Baseline cerebrospinal fluid (CSF) immune signature among participants who were diagnosed with HIV-associated CM showed distinct clusters by gender and by survival. PC - Principal component. Dots - show individual cytokines produced among participants projected on Eigenvector correlation covariates. Variables near the center (0; zero) are uncorrelated to the model and variables further away from the center (0; zero) are strongly correlated to the model. Variables among all cytokine projected on the variety of CSF cytokine patterns among participants by host survival (Figure 3A). The CSF secreted cytokines clustering by gender (Figure 3B). Cytokine clustering by female survival (Figure 3C). Cytokine clustering by men's survival (Figure 3D).

Group Analyzed	Participa gender	ents by	Participar Survival	nts by	Females Survival	by	Males Survival	by
PC summary	PC1	PC2	PC1	PC2	PC1	PC2	PC1	PC2
Eigenvalue	9.8	7.3	9.5	7.6	10.1	9.5	7.6	4.7
Proportion of variance (%)	30.6	22.7	29.7	23.9	31.7	29.7	23.9	14.6
Cumulative proportion of variance (%)	30.6	53.3	29.7	53.6	31.7	61.3	23.9	38.5

Adjacent Table to Figure 3: PC1 shows the highest variance of loading on a single vector. PC2 shows the cumulative variance of loading that is orthogonal to PC1 with a center 0. Yet negative variables show the presence of hidden (latent) variables that can be only determined through inference using mathematical modeling or through direct measurement alongside observed variables (those with positive variance on PCA). The great the Eigenvalues than one (1) the greater the predictability power of the variable in determining the hidden or latent variance to the outcome.

1. SUPPLEMENTARY MATERIALS

893

894

895

896

Supplementary Table S1. Reported gender-Associated Survival Among People with HIV-**Associated Cryptococcal Meningitis.**

Article	Number of cases	Females N (%)	Males N (%)	Total fatality N (%)	Female fatality N	Male fatality N (%)
Pappas 2004 ²⁸	70	13 (18.6)	57 (81.4)			
Boulware 2010 ²⁹	170	70 (48.0)	100 (58.0)	85 (50.0) *		
Baldassarre 2014	76	30 (39.5)	46 (60.5)	30 (39.5)	12 (40.0	18 (39.1)
Jarvis 2014 ²⁶	481	231 (48.0)	250 (52.0)	163 (34.0) #	79 (34.2)	84 (33.6)
Boulware 2014 9	177	84 (47.5)	93 (52.5)	67 (37.9)		
Rajasingham 2015 30	188	100	88 (47.0)	45 (24.0)*		
Meya 2015 ¹⁹	46	25 (63.0)		14 (30.0) =		
George 2017 ³¹	158	54 (34.1)	108 (65.9)	41 (26.0) *		
Rhein 2017 ³²	172		113 (66.0)	69 (40.0)		
Kashef Hamadani 2018 ³³	55	10 (18.2)	45 (81.8)			
Meya 2019 ³⁴	3359		1522* (47.1)	949 (28.3) ^		
Pastick 2019 35	821	334 (40.7)	587 (58.7)	334 (41.3)		

Lakoh 2020 ³⁶	8	7	1	2 (25.0) *		
Marr 2020 ³⁷	145	50 (35.5)	95 (65.5)			
Lee 2021 ³⁸	76	28 (36.8)	48 (63.2)	10 (80.3)		
Stadelman 2021 ⁷	977	400 (40.9)	577 (59.1)	445 (45.5)#	198 (50.0)	247 (43.0)
Kalata 2021 ³⁹	678		390 (57.5)	251 (37.0) #		
Mansoor 2021 40	29066	6787 (23.3)	22279 (76.6)	2877 (9.9) ^a		
Deiss 2021 41	87			33 (37.9) =		
Zhao 2021 42	386	83 (21.5)	303 (78.5)	58 (15.0) ^a	18 (21.7)	40 (15.2)
Jarvis 2022 ⁴³	814	323 (39.7)	491 (60.3)	218 (26.9) #		
Okurut (current)	380	150 (39.5)	230 (60.5)	173 (45.5)	79 (52.7)	94 (40.9)

^{* -} hospital deaths. = - 12 weeks deaths. # - 10 weeks deaths. $^{\land}$ - 24 weeks. a - all deaths.

903


919

920

921

922 923

924



Supplementary Figure 1. Spearman's correlation of regulatory elements IL-10 and PD-L1 by gender among multivariate predictors of gender-specific survival among females and males who died on antifungal treatment. A-C correlation of IL-10 with A - CCL11/Eotaxin, B - CXCL10/IP-10, and C -IL-15 among females and males who died on antifungal treatment, (i - ii, respectively). D – correlation of IL-8 with IL-15 among females and males who died on antifungal treatment. E-H – correlation of PD-L1 with E – IL12p70, F – IL-15, G – CXCL10, and H – CCL11 among females and males who

died on antifungal treatment (i - ii), respectively). Notable, among females and males who survived, the responses were similar and positively correlated across the panels.

926

927